News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TipRanks Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Adagio Medical has released an updated investor presentation detailing its ULTA technology and clinical program. Key highlights include the full enrollment of the FULCRUM‑VT pivotal trial, projected FDA PMA approval for its first-gen vCLAS in Q4 2026, and $7.7 million in cash as of …
Adagene Inc. reported a non-GAAP loss per share of $0.20 and revenue of $1.6M for the first half of 2026, with an adjusted net loss of $14.2M. The clinical-stage biotechnology company, focused on monoclonal antibody drugs for cancer in China, continues its capital-intensive development …
Adagene Inc. reported a widened net loss of $16.4 million for H1FY26, missing quarterly EPS estimates at $(0.20) compared to $(0.10) consensus. Despite the increased loss, revenue from collaboration milestones reached $1.6 million, and a recent capital raise extended the company's cash runway to …
Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular …
Adagene (Nasdaq: ADAG) reported financial results for the first half of 2026, showing $127.9 million in cash and cash equivalents, extending their runway into late 2028. The company highlighted progress with its lead candidate, muzastotug, including a 31% overall response rate in MSS colorectal …
This article announces that Adagio Medical Holdings Inc. has filed a Form 8K for August 11. The filing is related to the company's financial activities and is reported by Investing.com.
Adagio Medical reported a net loss of $6.7 million for Q2 2026 with no revenue, and ended the quarter with $7.7 million in cash. The company highlighted positive results from its FULCRUM-VT trial and the first patient treatment with its next-generation vCLAS Ultra catheter, …
Adagio Medical Holdings, Inc. reported its 2026 quarterly results, with revenue reaching $4.93M and a diluted loss per share of ($0.3). The company announced significant business highlights, including completing enrollment for the FULCRUM-VT pivotal IDE study, submitting a PMA for vCLAS, and launching the …
Adagene (NASDAQ:ADAG) CEO Peter Luo recently increased his holdings in the company by purchasing 22,966 shares at an average price of $3.65, totaling approximately $83,826. This transaction, along with an additional purchase of 279 shares the following day, boosted his ownership by 51.04%. Despite …
Adagene CEO Peter Luo has purchased 23,245 American Depositary Shares (ADS) at approximately $3.65 per share, totaling $84,763.97. Following this transaction, his directly held ADS position increased to 68,245 shares, in addition to 112,500 restricted stock units. This information was generated using AI based …
This page provides an interactive stock chart and related news for Adagene Inc. (ADRs) under the ticker US0053291078.SG on Yahoo Finance. The stock is currently trading at 3.7800 EUR
This document provides a company profile and introduction for Adagio Medical. It outlines the company's background, key operations, and overall business focus, serving as a foundational overview for understanding its market position and strategic direction.
This article provides an earnings forecast for Adagene Inc (ADAG), highlighting analyst ratings and price targets. Based on 7 analysts, the stock has a "Buy" consensus with a target price of USD 7.00, representing a 159.46% upside. The report includes current stock price, market …
Adagio Medical (NASDAQ: ADGM) shares climbed 22% in after-hours trading after the company announced the successful treatment of the first patient with its next-generation vCLAS Ultra ablation system under FDA Expanded Access. The new system aims to treat abnormal heart rhythms without open-heart surgery, …
Adagio Medical has successfully treated the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (ULTA) system under FDA Expanded Access. The new system aims to optimize usability and reduce procedure time for ventricular tachycardia (VT) patients, building on the proven safety and …
Adagio Medical has successfully treated its first patient with the next-generation vCLAS Ultra-Low Temperature Ablation system under FDA Expanded Access. This advanced system, designed for greater maneuverability and faster procedures, addresses ventricular tachycardia that has resisted other treatments, particularly in difficult-to-reach areas near critical …
This article details
This article provides a financial overview of Adagene Inc. (ADAG), including real-time stock quotes, market capitalization, and a detailed breakdown of its financial statements. It highlights the company's latest earnings report for FY2025, showing revenue of 7.67M and an EPS of -0.37, alongside various …
Sio Capital Management, LLC has reported a decrease in its beneficial ownership of Adagio Medical Holdings, Inc. (ADGM) common stock to 3.15%, or 698,989 shares, as of June 30, 2026. This position is below the 5% threshold for passive investment disclosure, with Sio Capital …
This article provides a technical analysis of Adagene Inc (ADAG), detailing its support, resistance, indicators, and moving averages. According to the analysis, the overall signal based on moving averages and other technical indicators is "Neutral", despite showing 6 buy signals for moving averages and …
This article provides an overview of Adagio Medical Holdings Inc (ADGM), including its current stock price and market capitalization. It highlights that revenue breakdown data by business and region has not yet been disclosed by the company. The page also mentions Finsights' role in …
This article provides a valuation analysis for Adagene Inc (ADAG), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. The report indicates that relevant data for these valuation metrics have not yet been disclosed by the company. It briefly shows the current …
This article provides a detailed cash flow statement for Adagio Medical Holdings Inc (ADGM), covering quarterly data for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and ADGM's performance in these areas, such as its …
This article provides an overview of Adagio Medical Holdings Inc (ADGM) focusing on its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents current …
This article provides a risk assessment for Adagene Inc (ADAG), detailing various metrics related to volatility, financial risk, and investment risk. It covers data points such as Beta, VaR, Maximum Drawdown, Volatility, Return-to-Drawdown Ratio, Skewness, Realised Volatility, and Liquidity measures over different timeframes. The …
This article provides the quarterly and annual income statements for Adagene Inc (ADAG), detailing its financial performance including total revenue, operating expenses, net income, and earnings per share across various fiscal periods. It also includes an FAQ section explaining how to interpret income statements …
This article provides a detailed cash flow statement for Adagene Inc (ADAG), including operating, investing, and financing cash flows, both quarterly and annually. It also includes frequently asked questions explaining the different types of cash flow and their significance for ADAG. The financial data …
This article details the shareholder structure of Adagene Inc (ADAG), highlighting its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over recent quarters, and a list of key shareholder activities including stake changes and ownership percentages. The …
This article from TradingKey provides a revenue breakdown for Adagene Inc (ADAG), detailing its business segments and regional revenue and profit contributions. As of the publication date, the company has not yet disclosed relevant financial data for the specified fiscal years (FY2020-FY2024). The only …
Adagene Inc. (NASDAQ:ADAG) has received a consensus "Buy" rating from analysts, with an average 12-month price target of $8.00. While Guggenheim reaffirmed a "Buy" rating with a $10.00 target, Weiss Ratings reiterated a "Sell" rating. Institutional investors collectively own 9.51% of the clinical-stage biopharmaceutical …
Search by ticker symbol or company name and select a result to open its chart.